Hubbry Logo
TAAR1TAAR1Main
Open search
TAAR1
Community hub
TAAR1
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
TAAR1
TAAR1
TAAR1
View on Wikipedia
from Wikipedia

TAAR1
Identifiers
AliasesTAAR1, TA1, TAR1, TRAR1, trace amine associated receptor 1, Trace amine receptor
External IDsOMIM: 609333; MGI: 2148258; HomoloGene: 24938; GeneCards: TAAR1; OMA:TAAR1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

134864

111174

Ensembl

ENSG00000146399

ENSMUSG00000056379

UniProt

Q96RJ0

Q923Y8

RefSeq (mRNA)

NM_138327

NM_053205

RefSeq (protein)

NP_612200

NP_444435

Location (UCSC)Chr 6: 132.64 – 132.66 MbChr 10: 23.8 – 23.8 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Trace amine-associated receptor 1 (TAAR1) is a trace amine-associated receptor (TAAR) protein that in humans is encoded by the TAAR1 gene.[5]

TAAR1 is a primarily intracellular amine-activated Gs-coupled and Gq-coupled G protein-coupled receptor (GPCR) that is primarily expressed in several peripheral organs and cells (e.g., the stomach, small intestine, duodenum, and white blood cells), astrocytes, and in the intracellular milieu within the presynaptic plasma membrane (i.e., axon terminal) of monoamine neurons in the central nervous system (CNS).[6][7][8][9]

TAAR1 is one of six functional human TAARs, which are so named for their ability to bind endogenous amines that occur in tissues at trace concentrations.[10][11] TAAR1 plays a significant role in regulating neurotransmission in dopamine, norepinephrine, and serotonin neurons in the CNS;[12][13][7][10] it also affects immune system and neuroimmune system function through different mechanisms.[14][15][16][17]

Endogenous ligands of the TAAR1 include trace amines, monoamine neurotransmitters, and certain thyronamines.[18][6] The trace amines β-phenethylamine, tyramine, tryptamine, and octopamine, the monoamine neurotransmitters dopamine and serotonin, and the thyronamine 3-iodothyronamine (3-IT) are all agonists of the TAAR1 in different species.[18][6][19] Other endogenous agonists are also known.[18] A variety of exogenous compounds and drugs are TAAR1 agonists as well, including various phenethylamines, amphetamines, tryptamines, and ergolines, among others.[18] There are marked species differences in the interactions of ligands with the TAAR1, resulting in greatly differing affinities, potencies, and efficacies of TAAR1 ligands between species.[18] Many compounds that are TAAR1 agonists in rodents are much less potent or inactive at the TAAR1 in humans.[18]

A number of selective TAAR1 ligands have been developed, for instance the TAAR1 full agonist RO5256390, the TAAR1 partial agonist RO5263397, and the TAAR1 antagonists EPPTB and RTI-7470-44.[18][20] Selective TAAR1 agonists are used in scientific research, and a few TAAR1 agonists, such as ulotaront and ralmitaront, are being developed as novel pharmaceutical drugs, for instance to treat schizophrenia and substance use disorder.[20][21][22]

The TAAR1 was discovered in 2001 by two independent groups, Borowski et al. and Bunzow et al.[19][23]

Discovery

[edit]

TAAR1 was discovered independently by Borowski et al. and Bunzow et al. in 2001. To find the genetic variants responsible for TAAR1 synthesis, they used mixtures of oligonucleotides with sequences related to G protein-coupled receptors (GPCRs) of serotonin and dopamine to discover novel DNA sequences in rat genomic DNA and cDNA, which they then amplified and cloned. The resulting sequence was not found in any database and coded for TAAR1.[19][23] Further characterization of the functional role of TAAR1 and other receptors from this family was performed by other researchers including Raul Gainetdinov and his colleagues.[18]

Structure

[edit]

TAAR1 shares structural similarities with the class A rhodopsin GPCR subfamily.[23] It has 7 transmembrane domains with short N and C terminal extensions.[24] TAAR1 is 62–96% identical with TAARs2-15, which suggests that the TAAR subfamily has recently evolved; while at the same time, the low degree of similarity between TAAR1 orthologues suggests that they are rapidly evolving.[19] TAAR1 shares a predictive peptide motif with all other TAARs. This motif overlaps with transmembrane domain VII, and its identity is NSXXNPXX[Y,H]XXX[Y,F]XWF. TAAR1 and its homologues have ligand pocket vectors that utilize sets of 35 amino acids known to be involved directly in receptor-ligand interaction.[11]

Gene

[edit]

All human TAAR genes are located on a single chromosome spanning 109 kb of human chromosome 6q23.1, 192 kb of mouse chromosome 10A4, and 216 kb of rat chromosome 1p12. Each TAAR is derived from a single exon, except for TAAR2, which is coded by two exons.[11] The human TAAR1 gene is thought to be an intronless gene.[25]

Tissue distribution

[edit]
Diagram of TAAR1 organ-specific expression and function
This diagram illustrates how TAAR1 activation induces incretin-like effects through the release of gastrointestinal hormones and influences food intake, blood glucose levels, and insulin release.[9] TAAR1 expression in the periphery is indicated with "x".[9]

To date, TAAR1 has been identified and cloned in five different mammal genomes: human, mouse, rat, monkey, and chimpanzee. In rats, mRNA for TAAR1 is found at low to moderate levels in peripheral tissues like the stomach, kidney, intestines[26] and lungs, and at low levels in the brain.[19] Rhesus monkey Taar1 and human TAAR1 share high sequence similarity, and TAAR1 mRNA is highly expressed in the same important monoaminergic regions of both species. These regions include the dorsal and ventral caudate nucleus, putamen, substantia nigra, nucleus accumbens, ventral tegmental area, locus coeruleus, amygdala, and raphe nucleus.[6][27] hTAAR1 has also been identified in human astrocytes.[6][14]

Outside of the human central nervous system, hTAAR1 also occurs as an intracellular receptor and is primarily expressed in the stomach, intestines,[26] duodenum,[26] pancreatic β-cells, and white blood cells.[9][26] In the duodenum, TAAR1 activation increases glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) release;[9] in the stomach, hTAAR1 activation has been observed to increase somatostatin (growth hormone-inhibiting hormone) secretion from delta cells.[9]

hTAAR1 is the only human trace amine-associated receptor subtype that is not expressed within the human olfactory epithelium.[28]

Location within neurons

[edit]

TAAR1 is a primarily intracellular receptor expressed within the presynaptic terminal of monoamine neurons in humans and other animals.[7][10][29] In model cell systems, hTAAR1 has extremely poor membrane expression.[29] A method to induce hTAAR1 membrane expression has been used to study its pharmacology via a bioluminescence resonance energy transfer cAMP assay.[29]

Because TAAR1 is an intracellular receptor in monoamine neurons, exogenous TAAR1 ligands must enter the presynaptic neuron through a membrane transport protein[note 1] or be able to diffuse across the presynaptic membrane in order to reach the receptor and produce reuptake inhibition and neurotransmitter efflux.[10] Consequently, the efficacy of a particular TAAR1 ligand in producing these effects in different monoamine neurons is a function of both its binding affinity at TAAR1 and its capacity to move across the presynaptic membrane at each type of neuron.[10] The variability between a TAAR1 ligand's substrate affinity at the various monoamine transporters accounts for much of the difference in its capacity to produce neurotransmitter release and reuptake inhibition in different types of monoamine neurons.[10] E.g., a TAAR1 ligand which can easily pass through the norepinephrine transporter, but not the serotonin transporter, will produce – all else equal – markedly greater TAAR1-induced effects in norepinephrine neurons as compared to serotonin neurons.

A 2016 study found that most TAAR1 was expressed in intracellular membranes near the nucleus and that 2.3% of TAAR1 was expressed at the cell surface.[30] In addition, TAAR1 signaling via the protein kinase A (PKA) pathway was predominantly associated with cell-surface TAAR1.[30]

TAAR1 ligands have also been found to enter neurons by transporters other than the monoamine transporters.[31][32][33]

Receptor oligomers

[edit]

TAAR1 forms GPCR oligomers with monoamine autoreceptors in neurons in vivo.[32][34] These and other reported TAAR1 hetero-oligomers include:

[note 2] in the TAAR1- D2sh example shows that TAAR1 can be located at cell membranes, and in the case of enterochromaffin cells in the gut epithelium, TAAR1 can be activated by high doses of dietary 'trace' amines, proximal to vesicles packed with catecholamines, impacting the vagal nerve system and CNS. This raises questions about where T1AM might find TAAR1 and cause similar unexpected nerve firing.

Ligands

[edit]
Trace amine-associated receptor 1
Transduction mechanismsGs, Gq, GIRKs, β-arrestin 2
Primary endogenous agonistsTyramine, β-phenylethylamine, octopamine, dopamine
AgonistsFull agonists: RO5166017, RO5256390, ulotaront, amphetamine, methamphetamine
Partial agonists: RO5203648, RO5263397, RO5073012, ralmitaront
Neutral antagonistsRTI-7470-44
Inverse agonistsEPPTB
Positive allosteric modulatorsNone known
Negative allosteric modulatorsNone known
External resources
IUPHAR/BPS364
DrugBankQ96RJ0
HMDBHMDBP10805

Agonists

[edit]

Endogenous

[edit]
For a more comprehensive list, see Trace amine § List of trace amines.

The known endogenous agonists of the TAAR1 include trace amines like β-phenethylamine (PEA), monoamine neurotransmitters like dopamine, and thyronamines like 3-iodothyronamine (T1AM).[12]

Trace amines are endogenous amines which act as agonists at TAAR1 and are present in extracellular concentrations of 0.1–10 nM in the brain, constituting less than 1% of total biogenic amines in the mammalian nervous system.[36] Some of the human trace amines include tryptamine, phenethylamine (PEA), N-methylphenethylamine, p-tyramine, m-tyramine, N-methyltyramine, p-octopamine, m-octopamine, and synephrine. These share structural similarities with the three common monoamine neurotransmitters: serotonin, dopamine, and norepinephrine. Each ligand has a different potency, measured as increased cyclic AMP (cAMP) concentration after the binding event. The rank order of potency for the primary endogenous ligands at the human TAAR1 is: tyramine > β-phenethylamine > dopamine = octopamine.[6][19] Tryptamine and histamine also interact with the human TAAR1 with lower potency, whereas serotonin and norepinephrine have been found to be inactive.[18][19][37][23]

Thyronamines are molecular derivatives of thyroid hormone involved in endocrine system function. 3-Iodothyronamine (T1AM) is one of the most potent TAAR1 agonists yet discovered. It also interacts with a number of other targets.[13][38][39] Unlike the monoamine neurotransmitters and trace amines, T1A is not a monoamine transporter (MAT) substrate, although it does still weakly interact with the MATs.[38][40] Activation of TAAR1 by T1AM results in the production of large amounts of cAMP. This effect is coupled with decreased body temperature and cardiac output.

Other endogenous TAAR1 agonists include cyclohexylamine, isoamylamine, and trimethylamine, among others.[18][22][41]

Exogenous

[edit]

Although amphetamine, methamphetamine, and MDMA are potent TAAR1 agonists in rodents, they are much less potent in terms of TAAR1 agonism in humans.[18][66][37][67] As examples, whereas amphetamine and methamphetamine have nanomolar potencies in activating the TAAR1 in rodents, they have micromolar potencies for TAAR1 agonism in humans.[18][66][37][43][67] MDMA shows very weak potency and efficacy as a human TAAR1 agonist and has been regarded as inactive.[18][66][37][68] Relatedly, it is not entirely clear whether agents like amphetamine and methamphetamine at typical doses produce significant TAAR1 agonism and associated effects in humans.[69][42][67][70] However, TAAR1 agonism and consequent effects by these drugs may be more relevant in the context of very high recreational doses.[42][67] TAAR1 activation has been found to have inhibitory effects on monoaminergic neurotransmission, and TAAR1 agonism by amphetamines may serve to auto-inhibit and constrain their effects.[71][69][72][54]

While some amphetamines are human TAAR1 agonists, many others are not.[37] As examples, most cathinones (β-ketoamphetamines), such as methcathinone, mephedrone, and flephedrone, as well as other amphetamines, including ephedrine, 4-methylamphetamine (4-MA), para-chloroamphetamine (PCA),[54] para-methoxyamphetamine (PMA), 4-methylthioamphetamine (4-MTA), MDEA, MBDB, 5-APDB, and 5-MAPDB, are inactive as human TAAR1 agonists.[69][37] Many other drugs acting as monoamine releasing agents (MRAs) are also inactive as human TAAR1 agonists, for instance piperazines like benzylpiperazine (BZP), meta-chlorophenylpiperazine (mCPP), and 3-trifluoromethylphenylpiperazine (TFMPP), as well as the alkylamine methylhexanamine (DMAA).[18][37][73] The negligible TAAR1 agonism with most cathinones might serve to enhance their effects and misuse potential as MRAs compared to their amphetamine counterparts.[69][72]

Monoaminergic activity enhancers (MAEs), such as selegiline, benzofuranylpropylaminopentane (BPAP), and phenylpropylaminopentane (PPAP), have been claimed to act as TAAR1 agonists to mediate their MAE effects, but TAAR1 agonism for BPAP and PPAP has yet to be assessed or confirmed.[74][75] Selegiline is only a weak agonist of the mouse TAAR1, with dramatically lower potency than amphetamine or methamphetamine, and does not seem to have been assessed at the human TAAR1.[45][75]

Antagonists and inverse agonists

[edit]

A few other less well-known TAAR1 antagonists have also been discovered and characterized.[81][77][82][80]

RO5073012 is an antagonist-esque weak partial agonist of the rodent and human TAAR1 (EmaxTooltip maximal efficacy = 24–35%).[18][62][83][84] Similarly, MDA and MDMA are weak to very weak partial agonists or antagonists of the human TAAR1 (Emax = 11% and 26%, respectively), albeit with very low potency.[18][37][43]

It has been claimed that rasagiline may act as a TAAR1 antagonist, but TAAR1 interactions have yet to be assessed or confirmed for this agent.[75]

Function

[edit]
Phenethylamine and amphetamine in a TAAR1-localized dopamine neuron
A pharmacodynamic model of amphetamine and TAAR1
via AADC
The image above contains clickable links
Amphetamine enters the presynaptic neuron across the neuronal membrane or through DAT.[10] Once inside, it binds to TAAR1 or enters synaptic vesicles through VMAT2.[10][85][86] When amphetamine enters synaptic vesicles through VMAT2, it collapses the vesicular pH gradient, which in turn causes dopamine to be released into the cytosol (light tan-colored area) through VMAT2.[85][87] When amphetamine binds to TAAR1, it reduces the firing rate of the dopamine neuron via G protein-coupled inwardly rectifying potassium channels (GIRKs) and activates protein kinase A (PKA) and protein kinase C (PKC), which subsequently phosphorylate DAT.[10][88][89] PKA phosphorylation causes DAT to withdraw into the presynaptic neuron (internalize) and cease transport.[10] PKC-phosphorylated DAT may either operate in reverse or, like PKA-phosphorylated DAT, internalize and cease transport.[10][86] Amphetamine is also known to increase intracellular calcium, an effect which is associated with DAT phosphorylation through a CAMKIIα-dependent pathway, in turn producing dopamine efflux.[90][91]


Monoaminergic systems

[edit]

Before the discovery of TAAR1, trace amines were believed to serve very limited functions. They were thought to induce noradrenaline release from sympathetic nerve endings and compete for catecholamine or serotonin binding sites on cognate receptors, transporters, and storage sites.[36] Today, they are believed to play a much more dynamic role by regulating monoaminergic systems in the brain.[92]

One of the downstream effects of active TAAR1 is to increase cAMP in the presynaptic cell via Gαs G-protein activation of adenylyl cyclase.[92][19][11] This alone can have a multitude of cellular consequences. A main function of the cAMP may be to up-regulate the expression of trace amines in the cell cytoplasm.[93] These amines would then activate intracellular TAAR1. Monoamine autoreceptors (e.g., D2 short, presynaptic α2, and presynaptic 5-HT1A) have the opposite effect of TAAR1, and together these receptors provide a regulatory system for monoamines.[10] Notably, amphetamine and trace amines possess high binding affinities for TAAR1, but not for monoamine autoreceptors.[10][7] The effect of TAAR1 agonists on monoamine transporters in the brain appears to be site-specific.[10] Imaging studies indicate that monoamine reuptake inhibition by amphetamine and trace amines is dependent upon the presence of TAAR1 co-localization in the associated monoamine neurons.[10] As of 2010, co-localization of TAAR1 and the dopamine transporter (DAT) has been visualized in rhesus monkeys, but co-localization of TAAR1 with the norepinephrine transporter (NET) and the serotonin transporter (SERT) has only been evidenced by messenger RNA (mRNA) expression.[10]

In neurons with co-localized TAAR1, TAAR1 agonists increase the concentrations of the associated monoamines in the synaptic cleft, thereby increasing post-synaptic receptor binding.[10] Through direct activation of G protein-coupled inwardly-rectifying potassium channels (GIRKs), TAAR1 can reduce the firing rate of dopamine neurons, in turn preventing a hyper-dopaminergic state.[94][88][89] Amphetamine and trace amines can enter the presynaptic neuron either through DAT or by diffusing across the neuronal membrane directly.[10] As a consequence of DAT uptake, amphetamine and trace amines produce competitive reuptake inhibition at the transporter.[95][10] Upon entering the presynaptic neuron, these compounds activate TAAR1 which, through protein kinase A (PKA) and protein kinase C (PKC) signaling, causes DAT phosphorylation.[96] Phosphorylation by either protein kinase can result in DAT internalization (non-competitive reuptake inhibition), but PKC-mediated phosphorylation alone induces reverse transporter function (dopamine efflux).[10][97]

Immune system

[edit]
See also: Neuroimmune system

Expression of TAAR1 on lymphocytes is associated with activation of lymphocyte immuno-characteristics.[16] In the immune system, TAAR1 transmits signals through active PKA and PKC phosphorylation cascades.[16] In a 2012 study, Panas et al. observed that methamphetamine had these effects, suggesting that, in addition to brain monoamine regulation, amphetamine-related compounds may have an effect on the immune system.[16] A recent paper showed that, along with TAAR1, TAAR2 is required for full activity of trace amines in PMN cells.[17]

Phytohaemagglutinin upregulates hTAAR1 mRNA in circulating leukocytes;[6] in these cells, TAAR1 activation mediates leukocyte chemotaxis toward TAAR1 agonists.[6] TAAR1 agonists (specifically, trace amines) have also been shown to induce interleukin 4 secretion in T-cells and immunoglobulin E (IgE) secretion in B cells.[6]

Astrocyte-localized TAAR1 regulates EAAT2 levels and function in these cells;[14] this has been implicated in methamphetamine-induced pathologies of the neuroimmune system.[14]

Clinical significance

[edit]

Low phenethylamine (PEA) concentration in the brain is associated with major depressive disorder,[19][36][98] and high concentrations are associated with schizophrenia.[98][99] Low PEA levels and under-activation of TAAR1 also appears to be associated with ADHD.[98][99][100] It is hypothesized that insufficient PEA levels result in TAAR1 inactivation and overzealous monoamine uptake by transporters, possibly resulting in depression.[19][36] Some antidepressants function by inhibiting monoamine oxidase (MAO), which increases the concentration of trace amines, which is speculated to increase TAAR1 activation in presynaptic cells.[19][11] Decreased PEA metabolism has been linked to schizophrenia, a logical finding considering excess PEA would result in over-activation of TAAR1 and prevention of monoamine transporter function. Mutations in region q23.1 of human chromosome 6 – the same chromosome that codes for TAAR1 – have been linked to schizophrenia.[11]

Medical reviews from February 2015 and 2016 noted that TAAR1-selective ligands have significant therapeutic potential for treating psychostimulant addictions (e.g., cocaine, amphetamine, methamphetamine, etc.).[7][8] Despite wide distribution outside of the CNS and PNS, TAAR1 does not affect hematological functions and the regulation of thyroid hormones across different stages of ageing. Such data represent that future TAAR1-based therapies should exert little hematological effect and thus will likely have a good safety profile.[101]

Research

[edit]

A large candidate gene association study published in September 2011 found significant differences in TAAR1 allele frequencies between a cohort of fibromyalgia patients and a chronic pain-free control group, suggesting this gene may play an important role in the pathophysiology of the condition; this possibly presents a target for therapeutic intervention.[102]

In preclinical research on rats, TAAR1 activation in pancreatic cells promotes insulin, peptide YY, and GLP-1 secretion;[103][non-primary source needed] therefore, TAAR1 is potentially a biological target for the treatment of obesity and diabetes.[103][non-primary source needed]

Lack of TAAR1 does not significantly affect sexual motivation and routine lipid and metabolic blood biochemical parameters, suggesting that future TAAR1-based therapies should have a favorable safety profile.[104]

See also

[edit]

Notes

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

TAAR1

View on Grokipedia
from Grokipedia
Trace amine-associated receptor 1 (TAAR1) is a (GPCR) belonging to the rhodopsin-like family of GPCRs, primarily activated by low-molecular-weight endogenous trace amines such as β-phenylethylamine (β-PEA), p-tyramine, and , which play a crucial role in modulating monoaminergic neurotransmission in the brain and peripheral tissues. Discovered in 2001 through genomic approaches identifying receptors responsive to trace amines, TAAR1 is encoded by the TAAR1 gene located on chromosome 6q23.2, a locus associated with susceptibility to and . Its activation leads to increased cyclic AMP (cAMP) levels via Gs protein coupling, influencing downstream signaling pathways that regulate , serotonin, and glutamate systems. Structurally, TAAR1 features the canonical seven-transmembrane domain architecture typical of class A GPCRs, with a recently resolved cryo-electron microscopy (cryo-EM) structure of the human TAAR1 (hTAAR1) in complex with the agonist Ro5256390 and Gs heterotrimer at 3.35 Å resolution, revealing key interactions in the orthosteric binding pocket involving aspartate residue D1033.32 and hydrophobic contacts with residues F2676.51 and F2686.52. This highlights a rigid extracellular loop 2 (EL2) forming a 2-turn that contributes to stabilization, as well as species-specific differences, such as the threonine-to-alanine substitution at position 1945.42 that affects potency in rodents compared to humans. Prior to this, based on related receptors like the serotonin family provided insights into potential binding modes for agonists like , which interacts with transmembrane helices TM3, TM5, and TM6. TAAR1's endogenous ligands are trace amines present at low concentrations (approximately 100 ng/g tissue) in the , including β-PEA, p-tyramine, and , which are metabolites of like and . Exogenous ligands encompass psychostimulants such as and 3,4-methylenedioxymethamphetamine (), which act as TAAR1 agonists to facilitate release, as well as selective agonists like (SEP-363856) and ralmitaront (RO6889450) developed for therapeutic use. Antagonists, such as EPPTB, have been identified but are less clinically advanced. Expression of TAAR1 is widespread, with high levels in the , particularly in monoaminergic regions like the , , , and , where it co-localizes with D2 and serotonin 5-HT1A receptors to modulate their activity. Peripherally, TAAR1 is found in the , intestines, kidneys, and immune cells, suggesting roles in metabolic regulation and immune function beyond . Physiologically, TAAR1 agonism inhibits midbrain and serotonergic neuronal firing while enhancing prefrontal transmission, contributing to regulation of mood, , reward processing, and stress responses. Therapeutically, TAAR1 has emerged as a promising target for neuropsychiatric disorders, with partial agonists like demonstrating efficacy in reducing positive and negative symptoms of in phase 2 trials (effect size 0.45 on PANSS scores), though subsequent phase 3 trials in 2023 did not meet primary endpoints due to high placebo response; it received FDA Designation in 2019 for and is under investigation in phase 3 trials for bipolar depression, anxiety, and as of 2025. Ongoing clinical trials explore its potential in Parkinson's psychosis, substance use disorders, and other conditions, with preclinical data indicating and anti-stress effects without the adverse motor side effects of traditional antipsychotics. Genetic variants in TAAR1 have been linked to and metabolic conditions, further underscoring its clinical relevance.

Discovery and Genetics

Discovery

The discovery of TAAR1, a member of the trace amine-associated receptor family, occurred independently in 2001 through genomic approaches targeting orphan G protein-coupled receptors (GPCRs). Borowsky et al. identified the rat ortholog (initially termed TA1) by performing degenerate PCR on rat genomic DNA using primers designed from the transmembrane domains of serotonin receptors, leading to the cloning of a full-length cDNA encoding a 332-amino-acid protein. Concurrently, Bunzow et al. cloned the rat trace amine receptor 1 (rTAR1) using similar bioinformatics and molecular biology techniques to screen for novel receptors responsive to biogenic amines. These efforts revealed TAAR1 as the founding member of a novel family of nine mammalian GPCRs, distinct from classical biogenic amine receptors due to their unique sequence homology and ligand sensitivity. Early functional characterization demonstrated that TAAR1 is potently activated by trace amines, endogenous compounds present at low concentrations in the and periphery. In heterologous expression systems, Borowsky et al. reported no detectable activation by β-phenylethylamine (β-PEA) but an EC50 of 4.3 μM for at human TA1, while showing weaker responses to and serotonin. Bunzow et al. confirmed this Gs-mediated cAMP signaling pathway, observing robust activation by p-tyramine (EC50 ≈ 69 nM), β-PEA (EC50 ≈ 240 nM), , and , which distinguished TAAR1 from adrenergic or receptors that typically require higher agonist concentrations or different signaling mechanisms. These assays highlighted TAAR1's role as a sensitive detector of trace amines, which circulate at nanomolar to micromolar levels and modulate monoaminergic . The receptor was named trace amine-associated receptor 1 (TAAR1) to reflect its specific responsiveness to these low-abundance endogenous ligands, a nomenclature that standardized the family across species. Subsequent studies in 2004 further solidified its classification as a GPCR with primary cAMP-mediated signaling, building on the initial findings to explore its physiological implications in neural circuits.

Gene and Expression

The TAAR1 gene is located on the long arm of human chromosome 6 at the cytogenetic band q23.2, within a compact cluster of nine trace amine-associated receptor (TAAR) genes spanning approximately 109 kb. This cluster includes three pseudogenes (TAAR3, TAAR4, and TAAR7), resulting in six functional genes in humans: TAAR1, TAAR2, TAAR5, TAAR6, TAAR8, and TAAR9. The TAAR1 gene itself is characterized by a simple structure, with its coding sequence contained entirely within a single exon, reflecting the intronless nature typical of many G protein-coupled receptor genes in this family. The coding region spans 1017 base pairs, encoding a 339-amino acid protein. The full genomic span of TAAR1 is approximately 16 kb, and alternative splicing is limited, primarily affecting the 5' untranslated region without altering the protein-coding sequence. Expression of the gene is tightly regulated by its promoter and upstream regulatory elements within the TAAR cluster, which coordinate low basal transcription levels across tissues. In neuronal and peripheral contexts, transcription is inducible, as demonstrated by upregulation in response to stimuli such as , which increases TAAR1 mRNA in immune cells like T lymphocytes within hours of exposure. This inducibility suggests involvement of signaling-responsive transcription factors, though specific promoter-binding elements remain under active characterization. Species variations in the TAAR1 highlight evolutionary differences in the receptor cluster. While TAAR1 is fully functional and under purifying selection in humans and mice, the overall TAAR cluster expands in , with mice possessing 15 intact TAAR genes compared to the six in humans; some additional TAAR genes function as pseudogenes due to disruptive mutations. In contrast, exhibit accelerated pseudogenization of non-TAAR1 genes in the cluster. TAAR1 mRNA shows conserved low basal expression patterns across these species, with inducibility in and peripheral tissues.

Molecular Structure and Signaling

Protein Structure

TAAR1 belongs to the class A subfamily of G protein-coupled receptors (GPCRs), featuring a canonical architecture with seven transmembrane α-helices (TM1–TM7) spanning the plasma membrane, three extracellular loops (ECL1–ECL3), and three intracellular loops (ICL1–ICL3). The is extracellular, while the is intracellular, facilitating interactions with signaling partners. ECL2 adopts a structured β-hairpin conformation with a short 2-turn helical segment, contributing to the stability of the ligand-binding pocket. The orthosteric binding site for amine ligands is a deep, enclosed pocket primarily formed by residues in TM3, TM5, TM6, and ECL2. Key interacting residues include Asp103^{3.32} in TM3, which forms a with the ligand's group; Phe267^{6.51} and Phe268^{6.52} in TM6, providing aromatic stacking; and Phe186 and Val184 in ECL2, which cap the pocket entrance. For coupling, the conserved Asp^{3.49}-Arg^{3.50}-Tyr^{3.51} (DRY) motif at the intracellular end of TM3 (residues Asp137, Arg138, and Tyr139) undergoes a conformational rearrangement upon , stabilizing the open intracellular crevice for Gs engagement. Structural insights into hTAAR1 derive from cryo-electron microscopy (cryo-EM) structures of the ligand-bound hTAAR1-Gs complex, resolved at 3.35 overall (3.0 in the orthosteric site), revealing two disulfide bridges between the and ECL1/ECL2 that rigidify the extracellular vestibule. Additional cryo-EM structures have been reported, including the human TAAR1 complex with (resolved at ~3.2 in 2024; PDB: 8W87), revealing subtle differences in the orthosteric pocket for amphetamine-like ligands compared to trace amines. Ligand binding induces outward tilting of TM6 and inward shifts in TM5, expanding the G protein-binding interface by approximately 5 . Prior to these determinations, homology models based on the β2-adrenergic receptor (e.g., PDB: 2RH1) were employed to predict the amine-binding pocket and helical arrangements. Post-translational modifications of TAAR1 include N-linked at residues on ECL2 (e.g., Asn184 in ortholog, conserved in ), which promotes proper folding in the and facilitates trafficking to the cell surface; disruption of this site impairs insertion and leads to retention in intracellular compartments.

Signaling Pathways

TAAR1, as a class A (GPCR), primarily transduces signals through coupling to the stimulatory subunit Gαs upon binding at the plasma , which promotes the exchange of GDP for GTP on Gαs and activates to increase intracellular cyclic AMP (cAMP) levels. This canonical pathway elevates cAMP, which in turn activates (PKA) and other downstream effectors to modulate cellular responses. The process can be summarized as: ligand-bound TAAR1 → Gαs-GTP exchange → activation → cAMP ↑. In addition to Gαs-mediated signaling, TAAR1 can engage secondary pathways, including β-arrestin recruitment, which contributes to receptor desensitization by uncoupling TAAR1 from G proteins and promoting its internalization via endocytosis. β-Arrestin binding is facilitated by prior phosphorylation of the receptor's C-terminal tail by G protein-coupled receptor kinases (GRKs), a regulatory mechanism common to many GPCRs that limits prolonged signaling. At higher agonist concentrations, TAAR1 exhibits potential coupling to inhibitory G proteins such as Gαi/o, which may suppress adenylyl cyclase activity and attenuate cAMP production. Species-specific variations influence TAAR1 signaling bias; for instance, TAAR1 (hTAAR1) displays a stronger for Gq coupling compared to mouse TAAR1 (mTAAR1) across multiple agonists, potentially affecting efficacy in subtype activation. In , intracellular TAAR1 pools may additionally couple to Gα13 to activate RhoA signaling, distinct from the primary plasma membrane Gαs pathway observed in both species.

Distribution and Localization

Tissue Distribution

TAAR1 exhibits high expression in specific regions of the human brain, including the , , and , as well as the and , based on RT-PCR and analyses. Moderate levels of TAAR1 mRNA and protein are observed in peripheral organs such as the , particularly in β-cells, the thyroid gland, the , including enteroendocrine cells in the stomach and intestines, and kidneys. In peripheral tissues beyond endocrine organs, TAAR1 is detected at lower levels in leukocytes, such as monocytes and lymphocytes, confirmed through RT-PCR, , and single-cell sequencing. TAAR1 expression is also present in various endocrine cells, such as those in the and gastrointestinal mucosa, contributing to its broad but generally low-abundance profile outside the . Developmentally, TAAR1 mRNA is undetectable in human embryonic stem cells but detectable and significant in fetal ventral midbrain dopaminergic progenitors by gestational day 52, with expression continuing in postnatal mature neurons in the during neuronal maturation and differentiation. Among the human trace amine-associated receptors (TAARs), TAAR1 displays the widest expression pattern, extending beyond olfactory epithelia to include significant central and peripheral sites, whereas most other TAAR subtypes (TAAR2-TAAR9) are either pseudogenes or restricted primarily to olfactory functions with minimal non-sensory expression.

Neuronal and Cellular Localization

TAAR1 exhibits predominant localization at the plasma membrane within the somatodendritic regions of neurons in the and , as well as serotonergic neurons in the , where it modulates monoaminergic . This surface expression enables TAAR1 to interact closely with monoamine transporters such as DAT and SERT in these neuronal compartments. Immunohistochemical studies have demonstrated of TAAR1 with DAT in a subset of neurons in both and , supporting its role in presynaptic and somatodendritic regulation. Under basal conditions, a significant portion of TAAR1 resides in intracellular pools, primarily retained in the , with limited trafficking to the plasma membrane. Upon agonist stimulation, such as with amphetamines or trace amines, TAAR1 undergoes redistribution from these intracellular compartments to the cell surface, facilitating enhanced signaling in discrete subcellular domains. This dynamic trafficking is observed in systems and neuronal models, where agonists promote translocation via interactions with vesicular membranes. TAAR1 engages in oligomerization, forming homo- and heterodimers that influence its stability and function. Homo-oligomers occur through symmetric interfaces, while heterodimerization with other GPCRs, such as the D2 receptor, promotes surface expression and modulates signaling specificity. Disulfide bonds, including a conserved linkage between residues in the second extracellular loop (ECL2) and transmembrane helix 3, contribute to dimer stabilization by maintaining the receptor's extracellular architecture. Evidence from structural analyses indicates these bonds are critical for agonist-induced conformational changes in oligomeric states. Studies have demonstrated colocalization of TAAR1 with DAT in neurons, highlighting proximity that supports coordinated transporter regulation. These findings underscore TAAR1's positioning at synaptic sites, where it influences and serotonin dynamics without direct membrane fusion events. In non-neuronal cells, TAAR1 demonstrates surface expression on activated T-lymphocytes, where its levels increase significantly following immune stimulation, such as with phytohemagglutinin, enabling immunomodulatory signaling via cAMP pathways. Similarly, TAAR1 localizes to the plasma membrane of pancreatic β-cells, contributing to glucose-dependent insulin through agonist-activated mechanisms.

Ligands and Pharmacology

Endogenous Ligands

The endogenous ligands of the trace amine-associated receptor 1 (TAAR1) primarily consist of trace amines, which act as full agonists with high potency. These include β-phenylethylamine (β-PEA), with an EC50 of approximately 40–900 nM; tyramine, with an EC50 of 70–1100 nM; octopamine; and tryptamine, all of which activate TAAR1 by stimulating cAMP production in heterologous expression systems. These ligands bind within the orthosteric pocket of TAAR1, where the protonated amine group forms a salt bridge with the conserved aspartate residue (Asp3.32) in transmembrane helix 3 (TM3), a mechanism conserved across aminergic G protein-coupled receptors. Classical monoamines, such as , norepinephrine, and serotonin, serve as partial agonists at TAAR1 but exhibit substantially lower potency, with EC50 values in the micromolar range ( ≈1.3 μM, norepinephrine ≈11 μM, serotonin ≈30 μM). This reduced efficacy compared to trace amines underscores TAAR1's primary role in responding to low-abundance biogenic amines rather than the more prevalent classical neurotransmitters. Additionally, thyronamines like 3-iodothyronamine (T1AM) function as potent full agonists at TAAR1, activating TAAR1 with an EC50 of 14 nM and mouse TAAR1 with 112 nM, while showing lower potency at human TAAR1 (EC50 ≈ 1.5 μM), eliciting robust cAMP signaling. In the mammalian , physiological concentrations of trace amines typically range from 10–100 nM, levels sufficient to modulate TAAR1 activity at discrete synaptic sites despite their low overall abundance relative to classical monoamines. This concentration profile supports TAAR1's function as a fine-tuned regulator responsive to endogenous trace amine fluctuations.

Synthetic Ligands

Synthetic ligands for the trace amine-associated receptor 1 (TAAR1) primarily include psychostimulants and pharmaceutical compounds that act as direct agonists, modulating cAMP production through activation. Amphetamines such as D-amphetamine and serve as prototypical exogenous agonists, exhibiting micromolar potency at TAAR1 across species. D-amphetamine displays an EC50 of approximately 1 μM at TAAR1, while has an EC50 of around 1 μM in but reduced potency (EC50 ≈ 4 μM) in humans. These compounds not only directly activate TAAR1 but also function as substrates, promoting TAAR1-mediated release, which contributes to their effects. Other psychostimulants, including and derivatives, exhibit partial agonism at TAAR1, influencing monoamine systems and associated behavioral outcomes like . acts as a full at human TAAR1 with an EC50 of 0.37–1.72 μM, while its metabolites, such as , show higher potency (EC50 ≈ 51 nM). 's norfenfluramine functions as a TAAR1 , though with lower compared to amphetamines, supporting its role in serotonergic modulation. Species-specific differences are notable, with amphetamines demonstrating higher potency (lower EC50) at rodent TAAR1 than at TAAR1, complicating . Therapeutic candidates have advanced TAAR1 agonism toward clinical applications, focusing on selective full or partial agonists. Ulotaront (SEP-363856) is a potent TAAR1 agonist with an EC50 of 38 nM at human TAAR1, displaying full efficacy (Emax = 109%) and selectivity over dopamine D2 receptors. Ralmitaront (RO6889450), a partial agonist, binds human TAAR1 with an EC50 of approximately 18 nM, emphasizing slower kinetics and reduced efficacy relative to full agonists like ulotaront. Research tools such as RO5263397 provide high selectivity, acting as a full agonist at human TAAR1 (EC50 = 17 nM) and suppressing dopamine-dependent hyperactivity in preclinical models. Recent cryo-EM structures (as of 2024) of TAAR1 with ligands like RO5263397 and LSD have elucidated diverse binding poses in the orthosteric pocket. These compounds highlight TAAR1's potential as a target for neuropsychiatric therapies, distinct from traditional monoamine reuptake inhibition.
CompoundHuman TAAR1 EC50 (nM)Notes
D-Amphetamine~1000Full ; species potency higher in
~1000–4440Direct and substrate; lower potency in humans
370–1720Full ; partial via metabolites
(SEP-363856)38Selective full
Ralmitaront (RO6889450)18
RO526339717Selective full for research

Antagonists and Modulators

TAAR1 antagonists inhibit receptor activation by endogenous trace amines or synthetic agonists, thereby modulating downstream signaling pathways such as cAMP accumulation and coupling. These compounds are primarily orthosteric binders that compete with agonists at the receptor's primary ligand-binding pocket, preventing conformational changes necessary for Gs protein activation. Unlike TAAR1 agonists, which enhance monoaminergic , antagonists reduce or inverse TAAR1-mediated effects, with potential applications in disorders involving excessive activity or hypodopaminergia. A prominent example of a TAAR1 inverse agonist is EPPTB (N-(3-ethoxy-phenyl)-4-pyrrolidin-1-yl-3-trifluoromethyl-benzamide), which not only blocks agonist-induced cAMP production but also suppresses basal receptor activity in cells overexpressing mouse TAAR1. EPPTB exhibits high potency at mouse TAAR1 (IC50 = 27.5 ± 9.4 nM for β-phenylethylamine-induced cAMP elevation) and reduces constitutive cAMP levels by approximately 10% (IC50 = 19 ± 12 nM), indicating inverse agonism at tonically active receptors. However, its affinity is substantially lower at human and rat orthologs (IC50 values of 7.5 μM and 4.5 μM, respectively), limiting its utility as a human-selective probe. By antagonizing TAAR1, EPPTB increases firing rates of dopamine neurons through blockade of inwardly rectifying channels, enhancing tone. Competitive antagonists of TAAR1 include low-potency compounds like Compound 22, identified through and exhibiting weak inhibition (IC50 > 100 μM) of TAAR1 signaling . This non-selective agent enhances - and cocaine-induced locomotor activity in at doses of 5–30 mg/kg, an effect observed even in TAAR1 mice, suggesting additional off-target interactions such as weak affinity for receptors (Ki values of 276 nM and 412 nM for sigma-1 and sigma-2). In contrast, the more potent and -selective antagonist RTI-7470-44 (discovered in 2022) displays an IC50 of 8.4 nM in TAAR1 cAMP assays and a Ki of 0.3 nM in radioligand binding, with over 90-fold selectivity versus (IC50 = 748 nM) and (IC50 = 1190 nM) receptors. RTI-7470-44 binds within the orthosteric site, stabilizing an inactive conformation that impedes agonist access and recruitment. Data on allosteric modulators of TAAR1 remain limited, with no well-characterized positive or negative allosteric regulators reported to date; however, structural studies suggest potential allosteric sites near the orthosteric pocket that could accommodate such ligands. Some atypical antipsychotics, including , exhibit weak interactions with TAAR1, potentially contributing to their polypharmacological profiles, though specific binding affinities (IC50 > 10 μM) have not been rigorously quantified for this receptor. In therapeutic contexts, TAAR1 antagonists like EPPTB and RTI-7470-44 hold promise for probing and treating hypodopaminergic conditions, such as or certain depressive states, by elevating neuron activity without directly impacting monoamine transporters. Unlike traditional stimulants, these agents may counteract psychostimulant abuse liability indirectly through enhanced dopaminergic homeostasis, though preclinical evidence primarily supports agonists for addiction treatment. Ongoing research emphasizes their role in dissecting TAAR1's contributions to monoaminergic dysregulation.

Physiological Roles

In Monoaminergic Neurotransmission

TAAR1 modulates monoaminergic neurotransmission primarily within circuits, exerting regulatory effects on and serotonin systems through presynaptic mechanisms. Activation of TAAR1 by endogenous trace amines or synthetic agonists stimulates Gs-coupled G-protein signaling, elevating intracellular cAMP levels and activating (PKA), which in turn inhibits dopamine D2 and serotonin 5-HT1A autoreceptors on presynaptic terminals. This enhances the release of and serotonin from neurons in regions such as the (VTA) and , thereby fine-tuning monoamine availability in synaptic clefts. Presynaptically, TAAR1 is localized on neurons in the VTA and (SN), where it influences neuronal excitability and firing patterns. Acute TAAR1 activation typically inhibits the firing rate of these neurons by opening inwardly rectifying channels, providing a tonic brake on activity to prevent hyperdopaminergia; in contrast, TAAR1 mice exhibit elevated basal firing rates, underscoring its modulatory role. Chronic activation, however, can increase firing rates and promote burst-like activity, contributing to sustained regulation of transmission. TAAR1 also interacts with monoamine transporters, including the (DAT), (NET), and (SERT), to indirectly potentiate their function. For instance, TAAR1 agonism facilitates reverse transport of via DAT, promoting efflux and reducing reuptake in a manner independent of traditional psychostimulant mechanisms, as demonstrated in DAT models. This interaction amplifies monoamine signaling without directly binding the transporters. In behavioral paradigms, TAAR1 activation produces antidepressant-like effects, such as decreased immobility time in the forced swim and tail suspension tests, likely through enhanced serotonergic transmission. It further regulates reward and locomotion by attenuating - or amphetamine-induced hyperlocomotion and , effects absent in TAAR1 mice, highlighting its role in dampening excessive monoamine-driven behaviors. Dysregulation of TAAR1 expression is linked to dopaminergic deficits in models; for example, MPTP-induced in mice results in reduced TAAR1 protein levels in the and mRNA levels in the , correlating with impaired monoamine .

In Immune and Peripheral Systems

TAAR1 is expressed in various immune cells, including T cells and macrophages, where it plays a role in modulating inflammatory responses. In peripheral macrophages, such as bone marrow-derived macrophages, of TAAR1 by agonists like RO5256390 inhibits purinergic-induced of tumor necrosis factor-alpha (TNF-α), acting downstream of pro-inflammatory metabolic shifts and TNF synthesis regulation through Gs-coupled elevation of cyclic AMP (cAMP) levels. This effect contrasts with observations in some contexts where trace amines may promote production, highlighting cell-type and stimulus-specific functions of TAAR1 in innate immunity. In peripheral metabolism, TAAR1 contributes to endocrine regulation beyond the . In the , TAAR1 is expressed in β-cells, where its activation by endogenous trace amines or synthetic agonists enhances glucose-stimulated insulin secretion via cAMP signaling, promoting β-cell proliferation and function in models. In the , TAAR1 localizes to follicular cells and may influence processing, potentially modulating the release and conversion of such as thyroxine (T4) to (T3), with 3-iodothyronamine (T1AM), a TAAR1 agonist derived from thyroid hormone metabolites, implicated in these regulatory effects. TAAR1 exhibits low-level expression in cardiovascular tissues, including the heart and vascular endothelium. Trace amines acting through TAAR1 can elicit dual effects on vascular tone, with evidence for potential vasodilation in certain beds like mesenteric arteries, mediated by endothelial-dependent mechanisms and cAMP elevation, alongside vasoconstrictive responses in others such as coronary arteries. In the gastrointestinal system, TAAR1 is present in enteric neurons, where it modulates . by gut microbe-derived trace amines, such as , enhances intestinal propulsion through TAAR1-serotonin signaling pathways, improving transit in mouse models and suggesting a role in maintaining gut . from TAAR1 mice supports its involvement in immune function, as these animals display altered inflammatory responses, including impaired in granulocytes to trace amines and potential dysregulation in leukocyte during immune challenges.

Clinical and Research Applications

Therapeutic Potential in Neuropsychiatric Disorders

TAAR1 agonists, such as , have shown promise in treating by modulating signaling to alleviate both positive and negative symptoms. In phase 2 clinical trials, demonstrated significant reductions in (PANSS) total scores compared to , with comparable to atypical antipsychotics like , while exhibiting a favorable safety profile. Although initial phase 3 trials (DIAMOND 1 and 2) in 2023 did not meet primary endpoints due to high responses, a 2025 meta-analysis of dose-response data indicated that higher doses around 100 mg provided meaningful symptom improvement without increased adverse events, supporting further development. Ongoing phase 3 studies, such as NCT06894212 evaluating in acutely psychotic patients, continue to explore its role in acute treatment of . In the context of , TAAR1 agonists rather than antagonists have demonstrated potential to attenuate the rewarding effects of psychostimulants like , , and . Preclinical evidence shows that TAAR1 activation inhibits release induced by these substances, reducing self-administration and reinstatement of drug-seeking behavior in animal models of dependence. This suggests therapeutic utility for treating use disorders, though clinical trials in humans remain limited. For depression and attention-deficit/hyperactivity disorder (ADHD), TAAR1 agonists enhance monoaminergic , offering preclinical support for rapid antidepressant effects and improved attention. Rodent studies indicate that TAAR1 activation promotes and reduces depressive-like behaviors in forced swim tests, potentially providing faster onset than traditional SSRIs. In ADHD models, agonists like SEP-363856 () improve cognitive function via balanced and norepinephrine modulation, though human clinical data are emerging primarily from trials showing secondary mood benefits. In , TAAR1 upregulation has been linked to of neurons and mitigation of L-DOPA-induced . Preclinical models demonstrate that TAAR1 agonists reduce abnormal involuntary movements by normalizing striatal signaling without exacerbating motor symptoms. A pilot clinical study with in Parkinson's patients with suggested symptom relief without motor worsening, particularly in those with . Overall, TAAR1-targeted therapies exhibit a favorable safety profile, with minimal extrapyramidal side effects attributed to their balanced modulation of monoaminergic pathways, avoiding the hyperdopaminergic seen in traditional antipsychotics. This reduced risk of motor disturbances enhances their appeal for long-term use in neuropsychiatric conditions.

Ongoing and

Recent studies in 2024 have advanced understanding of TAAR1's potential in neuropsychiatric disorders. Shajan et al. reviewed the role of TAAR1 agonists in modulating monoaminergic and systems, highlighting their promise for and related conditions through biased signaling pathways that enhance therapeutic efficacy while minimizing side effects. Similarly, Liu et al. (2023, with follow-up analyses in 2024 contexts) elucidated the structural basis of TAAR1 activation by agonists like , revealing key binding interactions that support development, including partial at TAAR1 for treatment. Clinical progress includes Roche's ralmitaront (RO6889450), a TAAR1 partial evaluated in Phase 2 trials for (NCT04512066, NCT03669640), which were discontinued following interim analyses indicating limited efficacy as monotherapy. New TAAR1 antagonists are being explored for species-specific applications in therapy. For instance, RTI-7470-44, a potent human-selective TAAR1 (IC50 ≈ 8 nM for hTAAR1, >700-fold selectivity over rodent orthologs), blocks agonist-induced effects in neurons and shows potential to mitigate psychostimulant without affecting baseline firing, aiding translation from preclinical models to human treatments. Biomarker research is identifying TAAR1 variants as predictors of therapeutic response. Polymorphisms in TAAR1, such as single variants (SNVs), have been linked to altered receptor function and heightened sensitivity to stimulants like , with certain alleles associated with increased intake and reduced aversion in genetic models. Additionally, (PET) imaging ligands are in development to quantify TAAR1 occupancy and expression ; [18F]TAAR1-2203 demonstrates high affinity, brain penetration, and specificity in preclinical and non-human studies, with recent validation as the first PET radioligand for TAAR1 imaging published in November 2025, enabling assessment of drug-target engagement in neuropsychiatric trials. Key challenges in TAAR1 include species differences in receptor , where human TAAR1 exhibits distinct binding and signaling compared to versions, complicating preclinical-to-clinical translation. There is also a need for pan-TAAR modulators to address potential compensatory roles of other TAAR subtypes in disease pathology. In the pharmaceutical pipeline, is advancing (SEP-363856), a TAAR1/5-HT1A , toward Phase 3 evaluations by 2026 for and adjunctive therapy in mood disorders, building on prior data despite earlier endpoint challenges.

References

  1. https://pubs.acs.org/doi/10.1021/acsptsci.2c00016
  2. https://www.nature.com/articles/s41467-023-44601-4
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3005101/
  4. https://www.cell.com/trends/neurosciences/fulltext/S0166-2236(22)00211-9
  5. https://www.sumitomo-pharma.com/news/20230731-1.html
  6. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1464550/full
  7. https://humgenomics.biomedcentral.com/articles/10.1186/s40246-024-00620-w
  8. https://www.pnas.org/doi/10.1073/pnas.151105198
  9. https://www.pnas.org/doi/10.1073/pnas.101446398
  10. https://www.omim.org/entry/609333
  11. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00680/full
  12. https://www.ncbi.nlm.nih.gov/nuccore/NM_138327.4
  13. https://www.genecards.org/cgi-bin/carddisp.pl?gene=TAAR1
  14. https://www.ensembl.org/id/ENSG00000146399
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC4673484/
  16. https://jlb.onlinelibrary.wiley.com/doi/10.1189/jlb.4A0814-395RR
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3593117/
  18. https://academic.oup.com/mbe/article/39/3/msac006/6503506
  19. https://bmcecolevol.biomedcentral.com/articles/10.1186/1471-2148-10-51
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC6849804/
  21. https://bpspubs.onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0706948
  22. https://www.rcsb.org/structure/8W87
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC2713717/
  24. https://www.mdpi.com/2073-4409/10/6/1518
  25. https://doi.org/10.1016/j.tins.2022.10.010
  26. https://doi.org/10.3389/fphar.2018.00645
  27. https://doi.org/10.1016/j.cell.2023.10.014
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC8922295/
  29. https://www.sciencedirect.com/science/article/pii/S0163725817301626
  30. https://www.proteinatlas.org/ENSG00000146399-TAAR1/tissue
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC6029583/
  32. https://www.proteinatlas.org/ENSG00000146399-TAAR1
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC10607858/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC9369307/
  35. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00987/full
  36. https://www.nature.com/articles/s41380-019-0469-2
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC8234161/
  38. https://www.mdpi.com/1422-0067/23/1/209
  39. https://pubmed.ncbi.nlm.nih.gov/37963465/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC2713119/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC4695389/
  42. https://doi.org/10.1042/BJ20090998
  43. https://doi.org/10.1038/nm1051
  44. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2017.00118/full
  45. https://www.nature.com/articles/srep38006
  46. https://doi.org/10.1124/mol.60.6.1181
  47. https://pubmed.ncbi.nlm.nih.gov/17218486/
  48. https://doi.org/10.1021/acsmedchemlett.1c00527
  49. https://www.caymanchem.com/product/41111/ralmitaront
  50. https://www.medchemexpress.com/ro5263397.html
  51. https://www.cell.com/cell-reports/fulltext/S2211-1247(24)00834-9
  52. https://www.pnas.org/doi/10.1073/pnas.0906522106
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC9730857/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC6131539/
  55. https://www.mdpi.com/1422-0067/25/15/8226
  56. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00279/full
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC7845786/
  58. https://doi.org/10.1073/pnas.1103029108
  59. https://doi.org/10.1016/j.bcp.2009.05.031
  60. https://doi.org/10.1073/pnas.0906522106
  61. https://doi.org/10.1124/jpet.107.134247
  62. https://doi.org/10.1016/j.ejphar.2015.06.019
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC11048016/
  64. https://doi.org/10.3389/fimmu.2022.1041390
  65. https://pubmed.ncbi.nlm.nih.gov/30670596/
  66. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00221/full
  67. https://doi.org/10.1111/j.1476-5381.2011.01706.x
  68. https://doi.org/10.1038/s41598-019-46627-5
  69. https://www.sciencedirect.com/science/article/pii/S104366182500235X
  70. https://doi.org/10.1189/jlb.0912433
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC10465394/
  72. https://pubmed.ncbi.nlm.nih.gov/40795331/
  73. https://clinicaltrials.gov/study/NCT06894212
  74. https://www.nature.com/articles/npp201488
  75. https://www.nature.com/articles/s41380-022-01739-9
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC6608178/
  77. https://www.neurology.org/doi/10.1212/CPJ.0000000000200175
  78. https://www.nature.com/articles/s41537-021-00190-z
  79. https://link.springer.com/article/10.1007/s00406-023-01580-3
  80. https://doi.org/10.3389/fpsyt.2024.1464550
  81. https://doi.org/10.1038/s41586-023-06775-1
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC10844839/
  83. https://clinicaltrials.gov/study/NCT03669640
  84. https://doi.org/10.1021/acschemneuro.2c00086
  85. https://pubmed.ncbi.nlm.nih.gov/41196333/
  86. https://news.us.sumitomo-pharma.com/2024-03-15-Sumitomo-Pharma-Enters-into-an-Agreement-to-Amend-the-Worldwide-Collaboration-and-License-Agreement-for-Four-Psychiatry-and-Neurology-Compounds-Including-Ulotaront-with-Otsuka
Add your contribution
Related Hubs
User Avatar
No comments yet.